The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell Lymphoma

Exclusion Criteria

• •1. Pregnant or lactating women; (female participants of reproductive potential must have a negative serum or urine pregnancy test);
• •2. Uncontrolled active infection, HIV infection, syphilis serology reaction positive;
• •3. Active hepatitis B or hepatitis C infection;
• •4. Recent or current use of glucocorticoid or other immunosuppressor;
• •5. With severe cardiac, liver, renal insufficiency, diabetes and other diseases;
• •6. Transaminase \>2.5ULN, Bilirubin \>3ULN，Creatinine\>1.25ULN
• •7. Participate in other clinical research in the past three months; previously treatment with any gene therapy products;
• •8. Researchers think of that does not fit to participate in the study, or other cases that affect the clinical trial results;